290 results on '"Travis, Simon P. L"'
Search Results
2. The continuing value of mesalazine as first-line therapy for patients with moderately active ulcerative colitis.
3. Exclusive Enteral Nutrition Mediates Beneficial Gut Microbiome Enrichment in Acute Severe Colitis.
4. Exclusive Enteral Nutrition Mediates Beneficial Gut Microbiome Enrichment in Acute Severe Colitis
5. Defactinib inhibits PYK2 phosphorylation of IRF5 and reduces intestinal inflammation
6. Endoscopy in Inflammatory Bowel Disease: Western Perspective—Europe
7. Efficacy of oral prolonged‐release mesalazine in moderately active ulcerative colitis
8. Chromoendoscopy versus autofluorescence imaging for neoplasia detection in patients with longstanding ulcerative colitis (FIND-UC): an international, multicentre, randomised controlled trial
9. Development of the Escalation of Therapy or Intervention (ETI) Calculator for Patients with Ulcerative Colitis Using ePROMs.
10. APOLLO Has Landed: PROMS and Histology in UC
11. Infliximab versus ciclosporin for steroid-resistant acute severe ulcerative colitis (CONSTRUCT): a mixed methods, open-label, pragmatic randomised trial
12. Authors’ reply: The Association Between Visceral Adipose Tissue and Stricturing Crohn’s Disease Behavior, Fecal Calprotectin and Quality of Life
13. Visceral Adipose Tissue Is Associated With Stricturing Crohn’s Disease Behavior, Fecal Calprotectin, and Quality of Life
14. Clinical Effect of Mirikizumab Treatment on Bowel Urgency in Patients with Moderately to Severely Active Ulcerative Colitis and the Clinical Relevance of Bowel Urgency Improvement for Disease Remission
15. Early management of acute severe UC in the biologics era: development and international validation of a prognostic clinical index to predict steroid response
16. Patient-reported Outcomes: the ICHOM Standard Set for Inflammatory Bowel Disease in Real-life Practice Helps Quantify Deficits in Current Care
17. Limited uptake of ulcerative colitis “treat‐to‐target” recommendations in real‐world practice
18. Predictors of long‐term outcomes in patients with acute severe colitis: A northern Indian cohort study
19. Endoscopy in Inflammatory Bowel Disease: Western Perspective—Europe
20. Analysis of the Gut Microbiome of Rural and Urban Healthy Indians Living in Sea Level and High Altitude Areas
21. Targeted versus universal tuberculosis chemoprophylaxis in 1968 patients with inflammatory bowel disease receiving anti‐TNF therapy in a tuberculosis endemic region
22. Predicting the Individual Risk of Acute Severe Colitis at Diagnosis
23. Early management of acute severe UC in the biologics era: development and international validation of a prognostic clinical index to predict steroid response.
24. Clinical Effect of Mirikizumab Treatment on Bowel Urgency in Patients with Moderately to Severely Active Ulcerative Colitis and the Clinical Relevance of Bowel Urgency Improvement for Disease Remission.
25. The impact of clinical experience on decision-making regarding the treatment and management of mild-tomoderate ulcerative colitis.
26. Effect of the 'Recruitment' Maneuver on Respiratory Mechanics in Laparoscopic Sleeve Gastrectomy Surgery
27. Medical Management of Crohn's Disease
28. Multinational evaluation of clinical decision-making in the treatment and management of mild-to-moderate ulcerative colitis
29. Beyond endoscopic mucosal healing in UC: histological remission better predicts corticosteroid use and hospitalisation over 6 years of follow-up
30. Patient-reported Goals in Inflammatory Bowel Disease: What’s the Problem?
31. Efficacy and safety of oral Pentasa (prolonged-release mesalazine) in mild-to-moderate ulcerative colitis: a systematic review and meta-analysis
32. Once-daily budesonide MMX in active, mild-to-moderate ulcerative colitis: results from the randomised CORE II study
33. Multinational evaluation of clinical decision-making in the treatment and management of mild-to-moderate ulcerative colitis.
34. Establishment of a validated central reading system for ileocolonoscopy in an academic setting.
35. Randomised clinical trial: exclusive enteral nutrition versus standard of care for acute severe ulcerative colitis
36. Targeted Nanomedicines for Cancer Therapy, From Basics to Clinical Trials
37. Fistulating Anal Crohn’s Disease: Results of Combined Surgical and Infliximab Treatment
38. Prevalence and long‐term outcome of sub‐clinical primary sclerosing cholangitis in patients with ulcerative colitis
39. Biosimilars in IBD: hope or expectation?
40. A basal gradient of Wnt and stem-cell number influences regional tumour distribution in human and mouse intestinal tracts
41. Secukinumab, a human anti-IL-17A monoclonal antibody, for moderate to severe Crohnʼs disease: unexpected results of a randomised, double-blind placebo-controlled trial
42. Acute upper gastrointestinal bleeding: identifying low risk patients
43. Mucosal healing in inflammatory bowel diseases: a systematic review
44. Modelling the benefits of an optimised treatment strategy for 5-ASA in mild-tomoderate ulcerative colitis.
45. Developing an instrument to assess the endoscopic severity of ulcerative colitis: the Ulcerative Colitis Endoscopic Index of Severity (UCEIS)
46. Acute upper gastrointestinal bleeding in the UK: patient characteristics, diagnoses and outcomes in the 2007 UK audit
47. Gut microbiome diversity in acute severe colitis is distinct from mild to moderate ulcerative colitis
48. NOX1 loss-of-function genetic variants in patients with inflammatory bowel disease
49. High mucosal cytomegalovirus DNA helps predict adverse short-term outcome in acute severe ulcerative colitis.
50. The European consensus on ulcerative colitis: new horizons?
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.